EyeGene Inc. (KOSDAQ:185490)
South Korea · Delayed Price · Currency is KRW 1,510.00
+55.00 (3.78%)
At close: Jan 26, 2026
EyeGene Revenue
EyeGene had revenue of 1.10B KRW in the quarter ending September 30, 2025, with 14.36% growth. This brings the company's revenue in the last twelve months to 4.10B, up 25.97% year-over-year. In the year 2024, EyeGene had annual revenue of 3.36B with 7.37% growth.
Revenue (ttm)
4.10B
Revenue Growth
+25.97%
P/S Ratio
16.55
Revenue / Employee
n/a
Employees
n/a
Market Cap
67.91B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 3.36B | 230.37M | 7.37% |
| Dec 31, 2023 | 3.13B | -2.17B | -40.96% |
| Dec 31, 2022 | 5.29B | 2.05B | 63.27% |
| Dec 31, 2021 | 3.24B | -121.31M | -3.61% |
| Dec 31, 2020 | 3.36B | -881.96M | -20.77% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Choong Ang Vaccine Laboratory | 39.19B |
| Naturalendo Tech | 21.87B |
| Ark Solutions | 21.50B |
| PanGen Biotech | 15.27B |
| NGeneBio | 9.98B |
| MOA Life Plus | 9.80B |
| HLB Pep | 4.89B |
| Quratis | 2.28B |